reason report
recap outlook increasingli lever biomolecul across
bottom line remain outperform-r given
view compani life scienc tool lst leader
unmatch scale reach research lab combin
number growth product serv key end-market includ
biomolecul grow consolid posit share
trade today better-than-expect organ growth y/i
life scienc solut lss segment strength bioproduct
china grow europ high singl digit growth vs softer
expect analyt technolog deliv growth driven
tough comp despit contribut lc-m posit upsid
specialti diagnost sd lab product servic lp
post stronger expect overal organ growth continu
remain outperform pt move
benefit grow bioprocess posit market
get increasingli lever biomolecul
bioprocess busi grow contribut strongli
quarter st loui facil largest contract develop
manufactur facil north america single-us
bioproduct believ volum revenu bioprocess
busi servic expand ww core singl use
bioprocess tool market accord estim
strength end market continu global print strong
quarter europ apac grow high-singl
digit rang china growth remain strong y/i despit tough
comp continu expand presenc
china clinic trial logist new custom demo center
shanghai european market also came stronger vs gener weaker
expect go quarter end market mostli saw sequenti
improv biopharma continu see doubl digit growth
diagnostics/healthcar grow high-single-digit academic/
govern grow mid singl digit industrial/appli end market
flat expect tough high-singl digit comp low-
outlook remain solid financi flexibl improv rais
revenu ep guid slightli amid strong perform
lower debt financ cost debt refinanc interest
cost half current adj cost debt replac
expect quarterli interest save leverag
ratio debt/adj ebitda cash invest
well posit continu invest deploy capit
strengthen posit biomolecular exposur
compani inform svb leerink llc research
revenu ep exclud charg amort intang
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
brammer also close believ potenti consolid contract
develop manufactur organ industri long term view
posit given sheer scale reput presenc lst market biopharma
academ channel industrial/environment diagnost deliv manag
forecast grow solidifi presenc emerg market asia-pacif
china revenu continu strength biopharma end-market view
sign slow near term inorgan growth continu remain
key prioriti next five year capit deploy
share current trade ev/ebitda slightli large-
mid-cap tool averag ev/ebitda given
impress growth deliv leverag biolog drug discoveri develop
product china emerg market tailwind still continu believ
continu hold posit lead lab tool suppli provid like continu
post strong growth expect trade line large- mid-cap tool averag
deliv ev/ebitda deriv price target appli multipl
ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report svb leerink estim
